Singapore markets closed

Castle Biosciences, Inc. (CSTL)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
24.25-0.17 (-0.70%)
As of 02:09PM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 675.00M
Enterprise value 460.84M
Trailing P/E 478.00
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)2.64
Price/book (mrq)1.68
Enterprise value/revenue 1.84
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 0.93
52-week change 36.78%
S&P500 52-week change 326.43%
52-week high 326.70
52-week low 39.26
50-day moving average 320.86
200-day moving average 319.44

Share statistics

Avg vol (3-month) 3255.8k
Avg vol (10-day) 3341.87k
Shares outstanding 527.61M
Implied shares outstanding 627.61M
Float 826.83M
% held by insiders 13.02%
% held by institutions 188.87%
Shares short (15 Apr 2024) 41.46M
Short ratio (15 Apr 2024) 47.73
Short % of float (15 Apr 2024) 45.45%
Short % of shares outstanding (15 Apr 2024) 45.29%
Shares short (prior month 15 Mar 2024) 41.42M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin -12.28%
Operating margin (ttm)-7.50%

Management effectiveness

Return on assets (ttm)-5.92%
Return on equity (ttm)-7.82%

Income statement

Revenue (ttm)250.72M
Revenue per share (ttm)9.28
Quarterly revenue growth (yoy)73.60%
Gross profit (ttm)N/A
EBITDA -29.15M
Net income avi to common (ttm)-30.8M
Diluted EPS (ttm)-1.13
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)239.21M
Total cash per share (mrq)8.66
Total debt (mrq)25.07M
Total debt/equity (mrq)6.23%
Current ratio (mrq)9.26
Book value per share (mrq)14.59

Cash flow statement

Operating cash flow (ttm)12.98M
Levered free cash flow (ttm)2.38M